Insights

Strategic Partnerships CymaBay Therapeutics has established strategic partnerships with organizations like Gilead Sciences, which presents potential sales opportunities through collaborations and joint ventures.

Investor Confidence Recent investments from reputable firms like Wetzel Investment Advisors Inc. indicate investor confidence in CymaBay Therapeutics, potentially opening doors for sales discussions and partnerships.

High Funding With funding reaching $259 million and successful mergers, CymaBay Therapeutics has the financial backing to explore new sales avenues, expand operations, and invest in sales initiatives.

Recognition in the Industry Being recognized in categories like Corporate Activity and Growth signifies CymaBay Therapeutics' industry relevance, potentially attracting business opportunities and partnerships with industry players.

Pipeline of Innovative Therapies The development of innovative therapies like Seladelpar for autoimmune liver diseases showcases CymaBay Therapeutics' potential for sales growth through new product offerings and market penetration strategies.

CymaBay Therapeutics Tech Stack

CymaBay Therapeutics uses 8 technology products and services including SAS, Veeva Vault, Google Font API, and more. Explore CymaBay Therapeutics's tech stack below.

  • SAS
    Business Intelligence
  • Veeva Vault
    Enterprise Content Management
  • Google Font API
    Font Scripts
  • Hootsuite
    Marketing
  • Microsoft
    Miscellaneous
  • Open Graph
    Miscellaneous
  • Amazon Web Services
    Platform As A Service
  • X-XSS-Protection
    Security

Media & News

CymaBay Therapeutics's Email Address Formats

CymaBay Therapeutics uses at least 1 format(s):
CymaBay Therapeutics Email FormatsExamplePercentage
FLast@cymabay.comJDoe@cymabay.com
96%
First.Last@cymabay.comJohn.Doe@cymabay.com
2%
FiLast@cymabay.comJoDoe@cymabay.com
1%
First-Last@cymabay.comJohn-Doe@cymabay.com
1%

Frequently Asked Questions

Where is CymaBay Therapeutics's headquarters located?

Minus sign iconPlus sign icon
CymaBay Therapeutics's main headquarters is located at 7575 Gateway Blvd Suite 110 Newark, California 94560 US. The company has employees across 1 continents, including North America.

What is CymaBay Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact CymaBay Therapeutics's main corporate office by phone at +1-510-293-8800. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is CymaBay Therapeutics's stock symbol?

Minus sign iconPlus sign icon
CymaBay Therapeutics is a publicly traded company; the company's stock symbol is CBAY.

What is CymaBay Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
CymaBay Therapeutics's official website is cymabay.com and has social profiles on LinkedIn.

How much revenue does CymaBay Therapeutics generate?

Minus sign iconPlus sign icon
As of July 2024, CymaBay Therapeutics's annual revenue reached $7.5M.

What is CymaBay Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
CymaBay Therapeutics's SIC code is 2834 - Pharmaceutical Preparations NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does CymaBay Therapeutics have currently?

Minus sign iconPlus sign icon
As of July 2024, CymaBay Therapeutics has approximately 110 employees across 1 continents, including North America. Key team members include Chief Financial Officer: H. S.Chief Regulatory And Compliance Officer: K. D.Vice President Regulatory Affairs: C. B.. Explore CymaBay Therapeutics's employee directory with LeadIQ.

What industry does CymaBay Therapeutics belong to?

Minus sign iconPlus sign icon
CymaBay Therapeutics operates in the Pharmaceutical Manufacturing industry.

What technology does CymaBay Therapeutics use?

Minus sign iconPlus sign icon
CymaBay Therapeutics's tech stack includes SASVeeva VaultGoogle Font APIHootsuiteMicrosoftOpen GraphAmazon Web ServicesX-XSS-Protection.

What is CymaBay Therapeutics's email format?

Minus sign iconPlus sign icon
CymaBay Therapeutics's email format typically follows the pattern of . Find more CymaBay Therapeutics email formats with LeadIQ.

How much funding has CymaBay Therapeutics raised to date?

Minus sign iconPlus sign icon
As of July 2024, CymaBay Therapeutics has raised $259M in funding. The last funding round occurred on Sep 11, 2023 for $259M.
CymaBay Therapeutics

CymaBay Therapeutics

Pharmaceutical ManufacturingCalifornia, United States51-200 Employees

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.

Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC).

Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.

Section iconCompany Overview

Headquarters
7575 Gateway Blvd Suite 110 Newark, California 94560 US
Phone number
+1-510-293-8800
SIC Code
2834 - Pharmaceutical Preparations
Stock Symbol
CBAY
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Employees
51-200

Section iconFunding & Financials

  • $259M

    CymaBay Therapeutics has raised a total of $259M of funding over 16 rounds. Their latest funding round was raised on Sep 11, 2023 in the amount of $259M.

  • $10M

    CymaBay Therapeutics's revenue is in the range of $10M

Section iconFunding & Financials

  • $259M

    CymaBay Therapeutics has raised a total of $259M of funding over 16 rounds. Their latest funding round was raised on Sep 11, 2023 in the amount of $259M.

  • $10M

    CymaBay Therapeutics's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.